A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study

Published:2021-04-19 Issue:3 Volume:35 Page:325-336
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Marafini Irene,Stolfi Carmine,Troncone Edoardo,Lolli Elisabetta,Onali Sara,Paoluzi Omero Alessandro,Fantini Massimo C.,Biancone Livia,Calabrese Emma,Di Grazia Antonio,Monteleone Ivan,Lenti Marco Vincenzo,Di Sabatino Antonio,Monteleone Giovanni

Funder

Celgene

NograPharma

Università degli Studi di Roma Tor Vergata

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-021-00482-x.pdf

Reference32 articles.

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–78. https://doi.org/10.1056/NEJMra0804647.

2. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307(5717):1920–5. https://doi.org/10.1126/science.1106442.

3. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16(1):51–60. https://doi.org/10.1046/j.1365-2036.2002.01140.x.

4. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380(9853):1590–605. https://doi.org/10.1016/S0140-6736(12)60026-9.

5. Digby-Bell JL, Atreya R, Monteleone G, Powell N. Interrogating host immunity to predict treatment response in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(1):9–20. https://doi.org/10.1038/s41575-019-0228-5.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments;Trends in Pharmacological Sciences;2024-09

2. Integration of Gut Mycobiota and Oxidative Stress to Decipher the Roles of C-Type Lectin Receptors in Inflammatory Bowel Diseases;Immunological Investigations;2024-08-08

3. Preclinical and phase I studies of an antisense oligonucleotide drug targeting IGF-1R in liver cancer;Future Oncology;2024-05-13

4. Discovery and characterization of stereodefined PMO-gapmers targeting tau;2024-05-09

5. The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7;Cardiovascular Diabetology;2024-01-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3